PURPOSE: We evaluated the effect of chlorhexidine (CHX) 0.12% rinses on the clinical and microbiologic manifestations of oral candidiasis in HIV-infected children. STUDY DESIGN: This was a cross-sectional, clinical intervention study of 38 HIV-positive children. Inclusion in the study was based on oral examination and positive oral culture for Candida. At baseline, subjects with no clinical lesions but who were culture-positive for Candida (N = 9) were placed on preventive therapy of CHX q.d. for 90 days. Subjects with clinical oral candidiasis (N = 9) were placed on therapeutic CHX b.i.d. All 38 subjects received oral exams at monthly intervals. At 90 days oral mucosal samples were again taken for Candida. Colony-forming units (CFU) were determined before and after CHX treatment. RESULTS: Of 18 culture-positive subjects, 12 were included in the CFU analyses. After 3 months of CHX oral rinse therapy, Candida was undetectable in 3 children; another 8 showed an average 2-fold reduction in CFU. In 1 child the number of CFU increased modestly. Overall, the average pre- and posttreatment mean CFU was 6.18 +/- 2.19 and 2.73 +/- 3.15, respectively (P = .009). Five patients with clinical oral candidiasis at baseline, including all 3 who had pseudomembranous candidiasis, were free of signs of disease at the end of the study. CONCLUSIONS: This study suggests that the topical disinfectant CHX may be a promising agent for treating and preventing oral candidiasis in HIV-infected children.
PURPOSE: We evaluated the effect of chlorhexidine (CHX) 0.12% rinses on the clinical and microbiologic manifestations of oral candidiasis in HIV-infectedchildren. STUDY DESIGN: This was a cross-sectional, clinical intervention study of 38 HIV-positive children. Inclusion in the study was based on oral examination and positive oral culture for Candida. At baseline, subjects with no clinical lesions but who were culture-positive for Candida (N = 9) were placed on preventive therapy of CHX q.d. for 90 days. Subjects with clinical oral candidiasis (N = 9) were placed on therapeutic CHX b.i.d. All 38 subjects received oral exams at monthly intervals. At 90 days oral mucosal samples were again taken for Candida. Colony-forming units (CFU) were determined before and after CHX treatment. RESULTS: Of 18 culture-positive subjects, 12 were included in the CFU analyses. After 3 months of CHX oral rinse therapy, Candida was undetectable in 3 children; another 8 showed an average 2-fold reduction in CFU. In 1 child the number of CFU increased modestly. Overall, the average pre- and posttreatment mean CFU was 6.18 +/- 2.19 and 2.73 +/- 3.15, respectively (P = .009). Five patients with clinical oral candidiasis at baseline, including all 3 who had pseudomembranous candidiasis, were free of signs of disease at the end of the study. CONCLUSIONS: This study suggests that the topical disinfectant CHX may be a promising agent for treating and preventing oral candidiasis in HIV-infectedchildren.
Authors: Brenda A McManus; Eleanor McGovern; Gary P Moran; Claire M Healy; June Nunn; Pádraig Fleming; Colm Costigan; Derek J Sullivan; David C Coleman Journal: J Clin Microbiol Date: 2011-03-02 Impact factor: 5.948
Authors: W Nittayananta; T A DeRouen; P Arirachakaran; T Laothumthut; K Pangsomboon; S Petsantad; V Vuddhakul; H Sriplung; S Jaruratanasirikul; M D Martin Journal: Oral Dis Date: 2008-06-21 Impact factor: 3.511
Authors: Jair C Leao; Camila M B Ribeiro; Alessandra A T Carvalho; Cristina Frezzini; Stephen Porter Journal: Clinics (Sao Paulo) Date: 2009-05 Impact factor: 2.365
Authors: J Thoden; A Potthoff; J R Bogner; N H Brockmeyer; S Esser; K Grabmeier-Pfistershammer; B Haas; K Hahn; G Härter; M Hartmann; C Herzmann; J Hutterer; A R Jordan; C Lange; S Mauss; D Meyer-Olson; F Mosthaf; M Oette; S Reuter; A Rieger; T Rosenkranz; M Ruhnke; B Schaaf; S Schwarze; H J Stellbrink; H Stocker; A Stoehr; M Stoll; C Träder; M Vogel; D Wagner; C Wyen; C Hoffmann Journal: Infection Date: 2013-09-14 Impact factor: 3.553